The price of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) shares last traded on Wall Street fell -2.68% to $1.09.
Based on available information, 3 analysts follow Citius Pharmaceuticals Inc. (NASDAQ:CTXR). The consensus rating among analysts is ‘Buy’. CTXR stock price is now -9.79% away from the 50-day moving average and -8.07% away from the 200-day moving average. The market capitalization of the company currently stands at $176.08M.
Among analysts, 0 rate the stock a hold while 3 rate it a buy.
With the price target of $4, Maxim Group recently initiated with Buy rating for Citius Pharmaceuticals Inc. (NASDAQ: CTXR).
A total of 8.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CTXR stock. A new stake in Citius Pharmaceuticals Inc. shares was purchased by CHELSEA COUNSEL CO during the first quarter worth $89,000. BOOTHBAY FUND MANAGEMENT, LLC invested $82,000 in shares of CTXR during the first quarter. In the first quarter, SQUAREPOINT OPS LLC acquired a new stake in Citius Pharmaceuticals Inc. valued at approximately $80,000. CITIGROUP INC acquired a new stake in CTXR for approximately $76,000. LIGHTHOUSE INVESTMENT PARTNERS, LLC purchased a new stake in CTXR valued at around $39,000 in the second quarter. In total, there are 73 active investors with 11.10% ownership of the company’s stock.
A candlestick chart of Citius Pharmaceuticals Inc. (NASDAQ: CTXR) showed a price of $1.1500 on Thursday morning. During the past 12 months, Citius Pharmaceuticals Inc. has had a low of $0.77 and a high of $1.71. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.60, and a quick ratio of 5.60. The fifty day moving average price for CTXR is $1.2045 and a two-hundred day moving average price translates $1.1854 for the stock.
The latest earnings results from Citius Pharmaceuticals Inc. (NASDAQ: CTXR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.07, missing analysts’ expectations of -$0.03 by -0.04. This compares to -$0.05 EPS in the same period last year. The company reported revenue of $10.69 million for the quarter, compared to $7.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 40.76 percent.
Citius Pharmaceuticals Inc.(CTXR) Company Profile
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
